BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9704721)

  • 1. Enhanced myelotoxicity due to granulocyte colony-stimulating factor administration until 48 hours before the next chemotherapy course in patients with small-cell lung carcinoma.
    Tjan-Heijnen VC; Biesma B; Festen J; Splinter TA; Cox A; Wagener DJ; Postmus PE
    J Clin Oncol; 1998 Aug; 16(8):2708-14. PubMed ID: 9704721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer.
    Woll PJ; Hodgetts J; Lomax L; Bildet F; Cour-Chabernaud V; Thatcher N
    J Clin Oncol; 1995 Mar; 13(3):652-9. PubMed ID: 7533825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.
    Graziano SL; Valone FH; Herndon JE; Crawford J; Richards F; Rege VB; Clamon G; Green MR
    Lung Cancer; 1996 Jun; 14(2-3):315-29. PubMed ID: 8794413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer.
    Bronchud M; Scarffe JH; Thatcher N; Crowther D; Souza LM; Alton NK; Testa NG; Dexter TM
    Behring Inst Mitt; 1988 Aug; (83):327-9. PubMed ID: 2467655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
    Brugger W; Frommhold H; Pressler K; Mertelsmann R; Kanz L
    Semin Oncol; 1995 Feb; 22(1 Suppl 2):3-8. PubMed ID: 7531368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
    Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.
    Steward WP; von Pawel J; Gatzemeier U; Woll P; Thatcher N; Koschel G; Clancy L; Verweij J; de Wit R; Pfeifer W; Fennelly J; von Eiff M; Frisch J
    J Clin Oncol; 1998 Feb; 16(2):642-50. PubMed ID: 9469353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of chemotherapy with carboplatin, epirubicin, and escalating dose of VP-16 with G-CSF support in extensive small cell lung cancer.
    Gridelli C; D'Aprile M; Palmeri S; Curcio C; Rossi A; Gebbia V; Veltri E; Pepe R; Pistillucci G; Bianco AR
    Am J Clin Oncol; 1996 Dec; 19(6):589-91. PubMed ID: 8931678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot study of increasing dose intensity of epirubicin and ifosfamide in patients with small cell lung cancer by using recombinant granulocyte colony-stimulating factor.
    Philip PA; Rea D; Mitchell K; Carmichael J; Harris AL; Talbot DC
    Clin Oncol (R Coll Radiol); 1999; 11(2):84-9. PubMed ID: 10378632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of ifosfamide, carboplatin, etoposide and GM-CSF in small cell lung cancer.
    Thongprasert S
    J Med Assoc Thai; 2000 May; 83(5):549-53. PubMed ID: 10863902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose intensity phase I/II trial with carboplatin, ifosfamide, etoposide and vincristine combined with filgrastim in patients with small-cell lung cancer.
    Hanauske AR; Korfel A; Perker M; Heinrich B; Schwab G; Graf M; Depenbrock H; Höffken G; Kreuser ED; Thiel E; Zwingers T; Berdel WE
    Oncology; 1997; 54(5):363-70. PubMed ID: 9260596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation.
    Leyvraz S; Perey L; Rosti G; Lange A; Pampallona S; Peters R; Humblet Y; Bosquée L; Pasini F; Marangolo M
    J Clin Oncol; 1999 Nov; 17(11):3531-9. PubMed ID: 10550151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
    Furuse K; Fukuoka M; Nishiwaki Y; Kurita Y; Watanabe K; Noda K; Ariyoshi Y; Tamura T; Saijo N
    J Clin Oncol; 1998 Jun; 16(6):2126-32. PubMed ID: 9626212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy.
    Crawford J; George M
    Semin Oncol; 1995 Jun; 22(3 Suppl 7):18-22. PubMed ID: 7541916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer.
    de Campos E; Radford J; Steward W; Milroy R; Dougal M; Swindell R; Testa N; Thatcher N
    J Clin Oncol; 1995 Jul; 13(7):1623-31. PubMed ID: 7602351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood.
    Pettengell R; Woll PJ; Thatcher N; Dexter TM; Testa NG
    J Clin Oncol; 1995 Jan; 13(1):148-56. PubMed ID: 7528271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report.
    Cairo MS; Shen V; Krailo MD; Bauer M; Miser JS; Sato JK; Blatt J; Blazar BR; Frierdich S; Liu-Mares W; Reaman GH
    J Pediatr Hematol Oncol; 2001 Jan; 23(1):30-8. PubMed ID: 11196267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of filgrastim vs. sequential filgrastim and molgramostim after dose-intensified carboplatin, cyclophosphamide, and etoposide: a phase I pilot study.
    Recchia F; De Filippis S; Torchio P; Rea S; Gulino A; Quaglino D; Frati L
    Am J Clin Oncol; 1997 Apr; 20(2):209-14. PubMed ID: 9124202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer.
    Crown J; Kritz A; Vahdat L; Reich L; Moore M; Hamilton N; Schneider J; Harrison M; Gilewski T; Hudis C
    J Clin Oncol; 1993 Jun; 11(6):1144-9. PubMed ID: 7684770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ifosfamide, cisplatin and etoposide (ICE) combined chemotherapy with recombinant human granulocyte colony-stimulating factor support in small cell lung cancer.
    Hastürk S; Kurt B; Kocabas A; Orüç O; Burgut R
    J Chemother; 1997 Feb; 9(1):66-71. PubMed ID: 9106021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.